MyoLine

Vincent Mouly

Head: Anne Bigot and Vincent Mouly

MyoLine provides immortalized lines of myoblasts or fibroblasts converted into muscle cells, isolated from healthy subjects or patients suffering from numerous neuromuscular diseases. Myoblast lines have been immortalized by hTERT and cdk4 transduction, and can undergo over 200 divisions in vitro without losing their differentiation capacity. Fibroblast lines are transduced first by hTERT (immortalization) and then by an inducible version of MyoD. They can then be amplified and differentiated in the presence of doxycycline. The use of these human cells isolated from patients is of interest because they carry the patient’s exact mutation in its own genetic environment, and enable innovative therapeutic approaches to be tested.

For several years now, these anonymized cell lines have been made available to the scientific community on a collaborative basis, and many international laboratories are already using them. Our efforts are aimed at encouraging and facilitating research into neuromuscular diseases and the development of therapeutic strategies. Some of these lines are also available to private entities under MTAs for a defined project and duration, when authorized by the patient’s initial consent.

In 2023, MyoLine immortalized 33 new cell lines, transferred 345 cell ampoules to academic and private teams in France and abroad, and co-authored 16 publications.
In 2023, MyoLine made available a new cell model: fibro-adipogenic progenitor cells (FAPs) derived from DMD and FSHD patients.

MyoLine is run by Anne Bigot and Vincent Mouly, co-directors, as well as Kamel Mamchaoui, Jessica Ohahana, and Mona Bensalah, and the trainees we welcome every year.